Latest revenue
$289.8M
as of 2026-03-31
Latest net income
$270.5M
as of 2026-03-31
Net margin
93.3%
as of 2026-03-31
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $12.13B
- Enterprise value
- $-2.95B
- P/E (trailing)
- 10.4×
- Forward P/E
- —
- P/B
- 2.13×
- Dividend yield
- 0.7%
- 52-wk high
- $157.92
- 52-wk low
- $116.73
- Beta
- —
- Shares out
- 77.6M
5-year trend
What this company does
Globe Life sells life and supplemental health insurance policies, primarily to middle-income American families through captive agents and direct-to-consumer channels. Premiums drive the business, with $3.6 billion in life and health premium income over nine months and $849 million in net investment income on its $20 billion bond-heavy portfolio. Earnings jumped 28% in Q3 on favorable policy benefit remeasurement gains of $158 million, while the company aggressively repurchased $689 million of stock year-to-date.
Generated from GL's filing dated 2026-02-25
Key risks
- Fixed-maturity portfolio sits at $17.80B fair value vs $18.95B amortized cost — a $1.15B unrealized loss limiting investment flexibility.
- Heavy buybacks ($689M YTD) and $2.71B total debt against $5.69B equity; leverage rising while AOCI remains -$1.97B.
- Earnings flattered by $174.7M YTD life-policy remeasurement gain; reversal of favorable assumption updates could materially compress reported benefits.
Generated from GL's filing dated 2026-02-25
Profitability
Net margin
19.4%
4.5%Return on equity
19.4%
18.6%Return on assets
3.8%
99.1%Leverage
Debt / equity
4.16×
542.3%Long-term debt / equity
0.39×
25.0%Debt / assets
80.6%
105.2%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | $289.8M | +3.3% | $270.5M | +6.3% | 93.3% |
Q4 2025 2025-12-31 | $5.15B | +4.5% | $266.1M | +4.3% | 5.2% |
Q3 2025 2025-09-30 | $286.0M | +0.4% | $387.8M | +28.0% | 135.6% |
Q2 2025 2025-06-30 | $282.2M | -1.2% | $252.7M | -2.2% | 89.6% |
Q1 2025 2025-03-31 | $280.6M | -0.7% | $254.6M | +0.1% | 90.7% |
Q4 2024 2024-12-31 | $4.92B | — | $255.2M | — | 5.2% |
Q3 2024 2024-09-30 | $285.0M | +6.8% | $303.0M | +17.9% | 106.3% |
Q2 2024 2024-06-30 | $285.6M | +9.3% | $258.4M | +20.0% | 90.4% |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Life Insurance · SIC 6311
Your notes
Keep private notes on GL — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$0
Insider selling
$70.4M
Net activity
−$70.4M
Distinct insiders
11
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns GL
No institutional holdings on file for GL yet.
Source: SEC Form 13F-HR. Updated quarterly (45-day filing lag).
Top questions investors are asking
- 1
Life policyholder benefits dropped to $381M on a $149.5M remeasurement gain—how much of Q3 EPS upside is recurring versus one-time assumption relief?
- 2
Health benefits ratio rose to 59% YTD ($692M/$1.13B) versus 60% prior year despite premium growth—what's driving claims trend and pricing response?
- 3
With $689M YTD buybacks and only $5.69B equity against $17.8B AFS securities carrying $1.15B unrealized losses, how are you defending statutory capital adequacy?
Refreshed when GL files a new report · last from 2026-02-25